Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
Propionil-L-carnitina - esta forma es adecuada para el tratamiento de sntomas relacionados con la circulacin sangunea, como enfermedades vasculares perifricas o hipertensin
Anti-Aging Properties: As a powerful antioxidant, glutathione helps reduce wrinkles, fine lines, and signs of aging by neutralizing free radicals
This makes it a strong daily option for dogs exposed to environmental stressors like pollutants, pesticides, and other sources of toxin buildup
Galal AA, Abd Elmajeed AA, Elbaz RA, Wafa AM, Elshazli RM
Gene expression analyses in blood cells from individuals with ASD reveal that sulforaphane induces a broad molecular response